{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:27Z","timestamp":1792145487298,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Over the past decade, cystic fibrosis transmembrane conductance regulator (CFTR) modulators have revolutionized the treatment of cystic fibrosis. Currently, 4 modulators are approved for clinical use: ivacaftor, lumacaftor, tezacaftor, and elexacaftor. Despite their clinical benefits, these drugs show significant pharmacokinetic variability and interindividual differences in therapeutic response. This review aimed to evaluate the available evidence supporting therapeutic drug monitoring of CFTR modulators and to highlight knowledge gaps that may limit its clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature review was conducted, focusing on elexacaftor, tezacaftor, and ivacaftor. Bioanalytical methods developed for quantifying these compounds in biological fluids were systematically analyzed, and reported drug concentration ranges were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Multiple analytical methods have been described for the quantification of CFTR modulators, showing varying degrees of sensitivity and suitability for clinical application. Reported plasma concentration ranges confirm a high degree of interindividual pharmacokinetic variability. However, the relationship between drug exposure, therapeutic efficacy, and safety outcomes remains only partially defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although CFTR modulators meet many of the established criteria for therapeutic drug monitoring, critical gaps persist, particularly regarding exposure\u2013response relationships and optimal sampling strategies. Addressing these issues will be essential to establish therapeutic drug monitoring as a reliable tool for personalizing CFTR modulator therapy in patients with cystic fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001408","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:00:44Z","timestamp":1762196444000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor: An Overview of Bioanalytical Methods"],"prefix":"10.1097","volume":"48","author":[{"given":"Alessia","family":"Cafaro","sequence":"first","affiliation":[{"name":"Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-427X","authenticated-orcid":false,"given":"Sebastiano","family":"Barco","sequence":"additional","affiliation":[{"name":"Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cangemi","sequence":"additional","affiliation":[{"name":"Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1891\/NN-2022-0007","article-title":"Cystic fibrosis: back to the basics","volume":"42","author":"Myer","year":"2023","journal-title":"Neonatal Netw"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front Pharmacol"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: new tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J Transl Med"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biocel.2014.01.024","article-title":"On the structural organization of the intracellular domains of CFTR","volume":"52","author":"Moran","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biocel.2014.02.004","article-title":"CFTR structure and cystic fibrosis","volume":"52","author":"Cant","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"suppl 1","key":"R6-20260108","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2014.03.009","article-title":"European cystic fibrosis society standards of care: framework for the cystic fibrosis centre","volume":"13","author":"Conway","year":"2014","journal-title":"J Cyst Fibros"},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"106381","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"Van Der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"R14-20260108","article-title":"Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica","volume":"47","author":"Pigliasco","year":"2023","journal-title":"Rev Rass Biochim Clin"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.12610","article-title":"Pharmacokinetic and drug-drug interaction profiles of the combination of tezacaftor\/ivacaftor","volume":"12","author":"Garg","year":"2019","journal-title":"Clin Transl Sci"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R18-20260108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/bcp.13324","article-title":"The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers","volume":"83","author":"Liddy","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.jcf.2021.04.005","article-title":"Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls","volume":"20","author":"van der Meer","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/biomedicines11071962","article-title":"Biological fluid microsampling for therapeutic drug monitoring: a narrative review","volume":"11","author":"Cafaro","year":"2023","journal-title":"Biomedicines"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","article-title":"Safe and effective variability-a criterion for dose individualization","volume":"34","author":"Holford","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R23-20260108","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcf.2017.06.005","article-title":"Bicarbonate in cystic fibrosis","volume":"16","author":"Kunzelmann","year":"2017","journal-title":"J Cyst Fibros"},{"key":"R25-20260108","first-page":"45","article-title":"Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption","volume":"23","author":"Barraclough","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/pharmaceutics11060286","article-title":"Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding","volume":"11","author":"Shah","year":"2019","journal-title":"Pharmaceutics"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ppul.26116","article-title":"Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis","volume":"57","author":"Lyman","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","article-title":"Quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using liquid chromatography with tandem mass spectrometry and its clinical applicability","volume":"43","author":"Vonk","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"123518","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous quantification of ivacaftor, tezacaftor, and elexacaftor in cystic fibrosis patients' plasma by a novel LC-MS\/MS method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"key":"R41-20260108","first-page":"1","article-title":"Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk","author":"Hansson","year":"2024","journal-title":"Anal Bioanal Chem"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"116322","DOI":"10.1016\/j.jpba.2024.116322","article-title":"A rapid LC-MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma","volume":"248","author":"Zheng","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"R43-20260108","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/FTD.0000000000001231","article-title":"Dried blood spot method development and clinical validation for the analysis of elexacaftor, elexacaftor-M23, tezacaftor, tezacaftor-M1, ivacaftor, ivacaftor carboxylate, and hydroxymethyl ivacaftor using LC-MS\/MS","volume":"46","author":"Vonk","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/pharmaceutics17020200","article-title":"A novel LC-MS\/MS method for the measurement of elexacaftor, tezacaftor and ivacaftor in plasma, dried plasma spot (DPS) and whole blood in volumetric absorptive microsampling (VAMS) devices","volume":"17","author":"Pigliasco","year":"2025","journal-title":"Pharmaceutics"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"124604","DOI":"10.1016\/j.jchromb.2025.124604","article-title":"Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS\/MS: doors open to the application of therapeutic drug monitoring in cystic fibrosis treatment","volume":"1258","author":"Wessels","year":"2025","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/molecules30091866","article-title":"A liquid chromatography-tandem mass spectrometry method for the quantification of cystic fibrosis drugs (caftors) in plasma and its application for therapeutic monitoring","volume":"30","author":"D'Atri","year":"2025","journal-title":"Molecules"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","article-title":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"23","author":"Vonk","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:01:38Z","timestamp":1767848498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001408","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"2025-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}